glecirasib
AXP000030.1 · Targeted small molecule
- Platform
- small molecule
- Targets
- KRAS
- Originator
- Jacobio Pharmaceuticals
- Sponsor
- Jacobio Pharmaceuticals; Shanghai Allist Pharmaceuticals (Greater China)
Names
Cross-references
- NCI Thesaurus
- C181904
- Wikidata
- Q138303900
- FDA UNII
- UP75WH4QKM
Approvals
No regulatory approval recorded.
Clinical trials (17)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07827261 | A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Not yet recruiting | Phase 2 | 2026-09 | 2028-12 | 36 | Non-small Cell Lung Cancer |
| NCT07601048 | A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment | Not yet recruiting | Phase 3 | 2026-06 | 2028-05 | 450 | KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment |
| NCT07670013 | SKB264 Plus Glecirasib in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study | Recruiting | Phase 2 | 2026-04-01 | 2028-01 | 43 | NSCLC |
| NCT07339839 | Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC | Not yet recruiting | Phase 1/2 | 2026-03-01 | 2027-09-30 | 42 | KRAS G12C; NSCLC Stage IV |
| NCT07164170 | A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib | Recruiting | Phase 2 | 2025-09-22 | 2028-12-30 | 86 | Non-Small Cell Lung Cancer |
| NCT06838338 | JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC | Active not recruiting | Phase 1 | 2025-03-20 | 2026-03 | 30 | Colorectal Cancer |
| NCT06563999 | Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. | Recruiting | Phase 2 | 2024-11-01 | 2027-11-01 | 120 | Lung Cancer Stage III; Mutation |
| NCT06416410 | JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation | Recruiting | Phase 3 | 2024-08-07 | 2029-09-30 | 392 | Advanced Non-squamous Non-small-cell Lung Cancer; Metastatic Non-squamous Non Small Cell Lung Cancer |
| NCT06162169 | A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects | Completed | Phase 1 | 2023-11-25 | 2024-02-20 | 66 | Healthy Subjects |
| NCT06008288 | A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. | Recruiting | Phase 2 | 2023-10-27 | 2026-12-31 | 88 | KRAS P.G12C; Pancreatic Cancer; Solid Tumor |
| NCT05920941 | Mass Balance Study of [14C]JAB-21822 | Completed | Phase 1 | 2023-07-08 | 2023-08-09 | 6 | Mass Balance Study in Healthy Subjects |
| NCT05875493 | A Food Effect Study of JAB-21822 in Healthy Subjects | Completed | Phase 1 | 2023-05-12 | 2023-06-14 | 18 | Food Effect in Healthy Participants |
| NCT05276726 | A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1 | Recruiting | Phase 1/2 | 2022-08-17 | 2027-08 | 104 | Non-small Cell Lung Cancer |
| NCT05288205 | Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation | Recruiting | Phase 1/2 | 2022-04-14 | 2027-03 | 240 | Colorectal Cancer; KRAS P.G12C; Non-small Cell Lung Cancer; Pancreatic Ductal Carcinoma |
| NCT05194995 | JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation | Active not recruiting | Phase 1/2 | 2022-02-17 | 2025-04-30 | 48 | Advanced Colorectal Cancer; Appendiceal Cancer; Small Intestinal Cancer |
| NCT05002270 | JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation | Completed | Phase 1/2 | 2021-09-03 | 2025-02-12 | 29 | Advanced Solid Tumor; CRC; NSCLC |
| NCT05009329 | A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China | Active not recruiting | Phase 1/2 | 2021-07-26 | 2026-08 | 315 | NSCLC; Solid Tumor |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41325755 | Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial. | The Lancet. Respiratory medicine | 2026 | cited by trial NCT05288205 |
| PMID 41344351 | Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials. | The lancet. Gastroenterology & hepatology | 2026 | cited by trial NCT05009329 |
| PMID 42384131 | The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation. | Human cell | 2026 | cited by trial NCT05009329 |
| PMID 39762419 | Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial. | Nature medicine | 2025 | cited by trial NCT05009329 |
| PMID 40333694 | JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2025 | cited by trial NCT05288205 |
| PMID 41037823 | Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials. | Cancer communications (London, England) | 2025 | cited by trial NCT05002270 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41994634 | Non-small cell lung cancer research: advances and persistent challenges. | Frontiers in oncology | 2026 | name in abstract: glecirasib |
| PMID 42511798 | KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone. | International journal of molecular sciences | 2026 | name in abstract: glecirasib |
| PMID 42551924 | [Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions]. | Gan to kagaku ryoho. Cancer & chemotherapy | 2026 | name in abstract: glecirasib |
| PMID 42587211 | Correction: The dynamic evolution of circulating tumor cells during glecirasib treatment predicts survival and resistance in gastrointestinal tumors with KRASG12C mutation. | Human cell | 2026 | name in title: glecirasib |
| PMID 42622884 | KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms. | Medical oncology (Northwood, London, England) | 2026 | name in abstract: glecirasib |
| PMID 42846599 | Glecirasib treatment in KRAS G12C-positive non-small cell lung cancer with leptomeningeal metastasis. | Frontiers in oncology | 2026 | name in title: glecirasib |
| PMID 43001251 | From "undruggable" to tractable: Therapeutic advances targeting Kristen rat sarcoma viral homolog glycine to cysteine mutation at codon 12 (KRAS G12C)-mutant cancers and emerging resistance mechanisms. | Cancer pathogenesis and therapy | 2026 | name in abstract: glecirasib |
| PMID 39825361 | KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors. | Journal of translational medicine | 2025 | name in abstract: JAB-21822 |
| PMID 39875337 | Design, Structure Optimization, and Preclinical Characterization of JAB-21822, a Covalent Inhibitor of KRASG12C. | Journal of medicinal chemistry | 2025 | name in title: JAB-21822 |
| PMID 40024323 | Small molecules for Kirsten rat sarcoma viral oncogene homolog mutant cancers: Past, present, and future. | European journal of pharmacology | 2025 | name in abstract: glecirasib |
| PMID 40304209 | Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312. | Cancer research communications | 2025 | name in title: glecirasib |
| PMID 41158041 | [Advances in Diagnosis and Targeted Therapy of KRASG12C Mutant Non-small Cell Lung Cancer]. | Zhongguo fei ai za zhi = Chinese journal of lung cancer | 2025 | name in abstract: glecirasib |
Notes
KRAS G12C. Approved China (NMPA, May 2025) as 艾瑞凯; China rights licensed to Allist 2024. Wikidata QID not confirmed.
How to cite
glecirasib (AXP000030.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000030.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.